Launch One Acquisition CORP 8-K filings

Launch One Acquisition Corp. shareholders approved an amendment to extend the deadline for completing a business combination from July 15, 2026, to January 15, 2027.

Launch One Acquisition Corp. has rescheduled its extraordinary general meeting to July 10, 2026, to vote on extending its business combination deadline.

Launch One Acquisition Corp. announced the appointment of Daniel Clifford Rogers to its Board of Directors and as Chair of the Audit Committee, replacing Dr. Risa Stack.

Launch One Acquisition Corp. has entered into a definitive Business Combination Agreement with Minovia Therapeutics Ltd., an Israeli mitochondrial therapy company, which will result in Minovia becoming a publicly traded company on Nasdaq under a new parent entity, Mito US One Ltd.

Launch One Acquisition Corp. and Minovia Therapeutics Ltd. have announced a definitive business combination agreement, valuing Minovia at $180 million, to create a Nasdaq-listed clinical-stage biotechnology company focused on mitochondrial therapies.

Launch One Acquisition Corp. will allow separate trading of its Class A ordinary shares and warrants starting September 3, 2024.

Launch One Acquisition Corp. successfully closed its initial public offering and a private placement, raising a total of $236 million, with $230 million placed in a trust account for a future business combination.

Launch One Acquisition Corp. successfully priced its initial public offering of 20 million units, with an additional 3 million units available through an over-allotment option, for a total of $230 million in gross proceeds.